Patanjali–IMA Controversy: Justice, Advertising and the Battle Over Ayurveda Through the Lens of Five Logical Questions

The Indian Medical Association (IMA) versus Patanjali Ayurved controversy is not merely a dispute concerning the advertisement of a company. Beneath it lie several larger questions concerning India’s healthcare system, the acceptance of Ayurveda, the credibility of modern medicine, the limits of advertising, consumer rights, and the power of the judiciary.

The central issues before the Supreme Court concerned misleading advertisements, claims relating to medicinal efficacy, and compliance with an undertaking given before the Court. Therefore, while discussing the matter, it is essential to maintain a distinction between claiming therapeutic efficacy for a medicine and giving hope or encouraging a positive mindset to a patient.

On this basis, the controversy can be examined through five logical lenses.

1. Incoherent Argument — Treating Death and the Treatment of Disease as the Same Question

An incoherent argument is one in which words may be placed together, but the logical relationship between them remains unclear.

Treatment of a disease and immortality are two entirely different propositions.

If a person takes a medicine for the treatment of a particular disease, it does not mean that the medicine has guaranteed freedom from death for the rest of that person's life. A human being may suffer from several diseases simultaneously. If a person is undergoing treatment for one disease but dies during that period because of another disease, an accident, or some other cause, the mere fact of death cannot establish that the medicine intended to treat the first disease was responsible for that death.

This is precisely why the language of pharmaceutical and healthcare claims matters.

“This medicine is useful in treating a particular disease” and “this medicine will protect you from death” are not the same claim.

From a commercial perspective also, this distinction is crucial. A pharmaceutical or healthcare company may make a claim concerning a specific therapeutic indication, but that claim must be evaluated within the context of that particular indication. It should not automatically be converted into a guarantee of life.

Therefore, the first question should be:

What exactly was claimed?

Not:

Could the medicine guarantee that the person would never die?

2. Shifting the Reason — Moving from Treatment of Disease to a Guarantee of Life

The second fallacy is Shifting the Reason—where a general character is challenged by attaching a special character to it and then attacking the original proposition on the basis of that added characteristic.

If an advertisement claims that a particular disease can be cured, the claim should be examined on the basis of clinical evidence, regulatory standards, and the actual language used in the advertisement.

But if the debate moves in the direction of:

“If this medicine can cure a disease, does that mean it can also prevent a person from dying?”

then the original medical claim has been altered.

This distinction becomes even more important in the context of COVID-19. During the pandemic, respiratory complications were among the serious consequences associated with the disease. Therefore, any claim relating to a formulation intended for respiratory symptoms or disease should be examined independently.

There is, however, an important qualification from Patanjali's perspective as well: expressions such as “clinically proven cure” should be used only where they are supported by adequate and acceptable clinical evidence. Likewise, while criticising such claims, it is equally necessary to establish precisely what the advertisement actually said.

The basic principle of commercial law is straightforward:

A claim should be tested in the form in which it was actually communicated to the consumer.

Neither is it appropriate to enlarge a company's claim into a “guarantee of immortality,” nor is it appropriate to dismiss the requirement of clinical evidence.

3. Shifting the Topic — Turning “Hope” and “Misleading Advertisement” into the Same Issue

The third fallacy is Shifting the Topic—setting aside the real question and introducing another question that is not directly relevant to the original controversy.

There are two separate questions here.

First: Can a company provide consumers with false or unsupported medical information?

Second: Should a person suffering from a serious disease be given hope, confidence, and a positive mindset?

The answer to the first question must come from advertising law and medical evidence.

The second question concerns psychology, patient behaviour, and human dignity.

The two should not automatically be placed in the same category.

If an energy drink advertisement says that it will give you “wings,” an ordinary consumer may understand this as metaphorical advertising. But a medicinal advertisement making a claim concerning therapeutic efficacy carries a different level of responsibility.

Nevertheless, an important commercial question remains.

If healthcare communication consists only of fear, uncertainty, and the language of disease, without giving the patient any hope, would that constitute responsible healthcare communication?

There is a profound difference between telling a patient:

“Your treatment is possible; remain positive and continue your prescribed treatment,”

and saying:

“Our medicine will certainly cure every person.”

The first may constitute psychological support; the second is a measurable medical claim.

Therefore, the strongest way to question the Court's concerns regarding advertising is not to ask, “How can giving a positive mindset possibly be wrong?” Rather, the more precise question is:

Was sufficient distinction maintained between positive patient communication and a misleading commercial claim during judicial scrutiny?

4. Fallacy of Reason — Turning Hope into Evidence and Evidence into Hope

The fourth question is the most difficult.

A positive mindset can have medical value. Psychology and behavioural medicine indicate that a patient's mental state can influence treatment adherence, stress management, and health-related behaviour.

But there is also a clear logical boundary.

A positive mindset is not a substitute for clinical efficacy.

If a patient believes in a medicine, that belief alone does not make the medicine clinically proven.

The reverse is equally important.

If the clinical evidence surrounding a medicine is questioned, it cannot automatically follow that the communication was misleading merely because the patient derived hope from it.

The real analytical test should therefore be:

What was the claim?
What evidence supported that claim?
What disease and population did the evidence relate to?
Did the advertisement make a claim larger than the available evidence?

This is where law and commerce intersect.

In pharmaceutical marketing, consumer trust is one of the greatest commercial assets. If a company makes a claim greater than its evidence supports, short-term sales may increase, but long-term brand credibility can be damaged.

Conversely, if regulators or courts fail to distinguish between evidence-based medical communication and legitimate patient encouragement, healthcare communication could become unnecessarily defensive.

Therefore, the objective of judicial scrutiny should not merely be to stop advertisements. It should also be to establish the boundaries of truthful healthcare communication.

5. Non-Ingenuity — Turning the Issue into a Battle Between Systems of Medicine

The fifth fallacy is Non-Ingenuity—when, instead of finding an appropriate answer to the original question, the debate is shifted into another domain.

India has a long tradition of Ayurveda. At the same time, modern medicine has achieved extraordinary advances in emergency care, surgery, antibiotics, critical care, and numerous other areas.

Therefore, the question should not be:

Ayurveda versus Allopathy—which one is superior?

The more meaningful question should be:

Which treatment is effective and safe for which disease, for which patient, and on what evidence?

Many people report having benefited from Ayurveda. Such experiences should not simply be dismissed. But anecdotal experience and controlled clinical evidence are not the same thing.

Similarly, the achievements of modern medicine do not mean that every Ayurvedic medicine or therapeutic claim is automatically false.

If an individual reports improvement from a traditional therapy in liver disease, chronic respiratory illness, or another serious condition, that experience may be worthy of scientific investigation. But it cannot be called “clinical proof” merely because it happened, nor can it be dismissed merely because it falls outside modern medicine.

COVID-19 made this debate even more intense. Some of the world's most medically advanced countries suffered enormous losses during the pandemic. This does not diminish the importance of modern medicine, but it does remind us that medical science is neither omniscient nor infallible.

The strength of science lies precisely in its ability to continuously revise its conclusions on the basis of evidence.

The Judiciary, Business and the Question of “Rip You Apart”

Another serious aspect of this controversy concerns judicial language and institutional power.

It is within the judiciary's authority to scrutinise a company's advertisements, particularly when consumer protection and statutory compliance are involved. But when judicial authority is exercised, language becomes equally important.

A company should receive the clear message that:

Compliance with the law is mandatory, but compliance must be assessed on the basis of evidence and reason.

A judicial observation against a corporate entity can have significant commercial consequences—affecting brand value, consumer confidence, investors, employees, and business partners.

Therefore, judicial accountability and corporate accountability are both necessary.

If a company gives an undertaking before the Court and subsequently violates it, it must face the consequences.

But if, on the other hand, a statement or factual inference made during judicial proceedings subsequently proves to be incorrect, a legitimate question arises:

Should there also be a mechanism for institutional correction and apology?

The dignity of justice does not arise only from imposing severe consequences. It also comes from accurate facts, sound reasoning, and institutional self-correction.

Conclusion: The Real Battle Is Not Patanjali vs. IMA

Reducing the Patanjali–IMA controversy to “Ayurveda versus Allopathy” diminishes the complexity of the dispute.

The real issues are fivefold:

First, a claim regarding the treatment of a disease should not be transformed into a guarantee of immortality.

Second, an advertisement should be tested according to the actual claim it makes.

Third, a clear distinction should be maintained between misleading advertising and giving hope to a patient.

Fourth, a positive mindset should not be treated as a substitute for clinical evidence; but neither should patient psychology be treated as irrelevant merely because clinical evidence is being scrutinised.

Fifth, rather than turning Ayurveda and modern medicine into opposing camps, India should move towards evidence-based comparative healthcare.

Ultimately, a patient needs three things—truth, treatment, and hope.

The law must protect truth.

Medicine must provide treatment.

And, as human beings, we must recognise the importance of giving patients hope.

Instead of making these three principles enemies of one another, if India's judiciary, medical institutions, and healthcare industry can establish a balance among them, the Patanjali–IMA controversy can become more than a question of victory or defeat for one institution.

It can become an important precedent for the future of healthcare communication in India.

Because a patient does not need a false guarantee—but neither should a patient be sentenced to hopelessness.